Search research articles
Contact Us
Filters
Showing results (71-80 of 88) with videos related to
Page
of 9
Sort By:
Critical Reviews in Oncology/Hematology
|
October 26, 2005
Treatment of older patients with AML
Thomas Büchner, Wolfgang E Berdel, Bernhard Wörmann, et al.
European Urology
|
September 27, 2023
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)
Viktor Grünwald, Philipp Ivanyi, Stefanie Zschäbitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2012
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer, Paula Cramer, Raymonde Busch, et al.
Cytometry. Part B, Clinical Cytometry
|
August 15, 2006
Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process
Remi Letestu, Andy Rawstron, Paolo Ghia, et al.
Blood
|
January 10, 2009
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG
Jan Braess, Karsten Spiekermann, Peter Staib, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2003
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies
Torsten Haferlach, Claudia Schoch, Helmut Löffler, et al.
Journal of the National Cancer Institute
|
December 12, 2017
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
Oleg Gluz, Ulrike Nitz, Cornelia Liedtke, et al.
Genome Biology
|
January 21, 2011
Comparative and functional genomics provide insights into the pathogenicity of dermatophytic fungi
Anke Burmester, Ekaterina Shelest, Gernot Glöckner, et al.
Cardio-Oncology (London, England)
|
July 4, 2025
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial
Lisa B Leypoldt, Linlin Guo, Britta Besemer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
Lisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 88) with videos related to
Sort By:
Page
of 9
Critical Reviews in Oncology/Hematology
|
October 26, 2005
Treatment of older patients with AML
Thomas Büchner, Wolfgang E Berdel, Bernhard Wörmann, et al.
European Urology
|
September 27, 2023
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)
Viktor Grünwald, Philipp Ivanyi, Stefanie Zschäbitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2012
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer, Paula Cramer, Raymonde Busch, et al.
Cytometry. Part B, Clinical Cytometry
|
August 15, 2006
Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process
Remi Letestu, Andy Rawstron, Paolo Ghia, et al.
Blood
|
January 10, 2009
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG
Jan Braess, Karsten Spiekermann, Peter Staib, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2003
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies
Torsten Haferlach, Claudia Schoch, Helmut Löffler, et al.
Journal of the National Cancer Institute
|
December 12, 2017
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
Oleg Gluz, Ulrike Nitz, Cornelia Liedtke, et al.
Genome Biology
|
January 21, 2011
Comparative and functional genomics provide insights into the pathogenicity of dermatophytic fungi
Anke Burmester, Ekaterina Shelest, Gernot Glöckner, et al.
Cardio-Oncology (London, England)
|
July 4, 2025
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial
Lisa B Leypoldt, Linlin Guo, Britta Besemer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma
Lisa B Leypoldt, Diana Tichy, Britta Besemer, et al.
Page
of 9